Allergy Therapeutics Advances Peanut Allergy Vaccine Trial to Final Phase

An announcement from Allergy Therapeutics ( (GB:AGY) ) is now available.

Allergy Therapeutics has advanced to the final phase of its VLP Peanut Phase I/IIa PROTECT trial, with healthy volunteers receiving the highest doses without any safety signals. The trial aims to establish a strong safety margin and determine the optimal dose range for future studies. The company also announced a new publication validating the vaccine’s mechanism of action, highlighting its potential to reduce allergic responses and promote protective immune mechanisms. The results are promising for addressing the unmet need for effective peanut allergy treatments and could lead to long-term protection.

More about Allergy Therapeutics

Allergy Therapeutics is a fully integrated commercial biotechnology company specializing in allergy immunotherapies. The company focuses on developing innovative treatments for allergies, with a particular emphasis on peanut allergy, a growing public health concern in the US and Europe.

Average Trading Volume: 400,421

Technical Sentiment Signal: Sell

Current Market Cap: £309.8M

See more insights into AGY stock on TipRanks’ Stock Analysis page.